Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jan. 24, 1:55 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #15 of 100 |
Slide #15. Prestige Brands — Hydralyte
Acquirer:
Prestige Brands (NYSE:PBH)
Acquiree:
Hydralyte
Details:
Prestige Brands Holdings, Inc. (NYSE-PBH) today announced the signing of a purchase agreement for the acquisition of Hydralyte in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia. The acquisition is expected to close, subject to customary closing conditions, during the first quarter of fiscal 2015, which began on April 1, 2014.
Prestige Consumer Healthcare is a holding company. Through its subsidiaries, Co. develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare products to mass merchandisers and drug, food, dollar, convenience, club and e-commerce stores in North America and in Australia and certain other international markets. Co.'s portfolio of OTC Healthcare products includes, among others, Clear Eyes eye and ear care products, Compound W wart removal, Chloraseptic sore throat liquids and lozenges, DenTek oral care products, Luden's cough drops, Monistat women's health products, Nix lice and parasite treatment products and Fess Nasal Saline Sprays and Washes.
PBH SEC Filing Email Alerts Service
Open the PBH Page at The Online Investor »
|
||||||||||||||||||||||||
Open the PBH Page at The Online Investor (in a new window) »
 Free PBH Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Hold (2.50 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Analysts' Target Price: PBH Stock Forecast Based on Zacks ABR data; powered by Xignite |
